Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-escalation study of ularitide in pulmonary arterial hypertension (UPAH)
2020-004815-29Phase 2Terminated
- Sponsor
- Cardiorentis AG
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ularitide in pulmonary arterial hypertension (PAH), sponsored by Cardiorentis AG. Started Mar 2021; status: terminated.
02
Drugs
ularitide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2020-004815-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004815-29.